A Phase 3 Study of HS-20094 in Patients With T2DM
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 546 participants.
Also called NCT07156539
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 546 participants
- Registry
-
NCT07156539
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07156539. Randomized; no masking; primary purpose treatment. Start 2025-09-30 (anticipated); primary completion 2027-03-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 3 Study of HS-20094 in Patients With T2DM
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- HS-20094 Injection
- Intervention (Drug)
- Dulaglutide Injection
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct07156539- Content hash
63125461f974a7c0e443bce49dd2de65cd6a4e6af13945c00dad5e4bb8d1441d